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Abstract: Chlamydia trachomatis IgG antibody testing (CAT) has been used as a screening test for tubal
factor infertility (TFI), but as the CAT is only a marker of a past exposure to C. trachomatis and not of
late sequelae, the positive predictive value (PPV) of the test is low. The persistence of C. trachomatis
in the upper genital tract has been suggested as one of the key mechanisms in the development of
TFI. Serum antibodies against C. trachomatis TroA and HtrA, proteins expressed specifically during
persistent infection, have been suggested as novel biomarkers for TFI diagnostics. We studied
serum IgG antibody responses against C. trachomatis TroA, HtrA and MOMP in 79 subfertile women,
of whom 28 had laparoscopically proven TFI. We confirmed that the accuracy of CAT in diagnosing
TFI is low, whereas TroA IgG and HtrA IgG are more accurate tests in detecting tubal occlusion
and pelvic adhesions. However, the sensitivity and negative predictive value (NPV) of TroA IgG
and HtrA IgG are still too low to justify their use as a screening test in clinical practice. Individual
immunogenetic profiles combined with TroA and HtrA antibody responses might identify women
with the highest risk for developing late complications after C. trachomatis infection.
Keywords: Chlamydia trachomatis; tubal factor infertility; laparoscopy; Chlamydia trachomatis IgG
antibody testing
1. Introduction
Chlamydia trachomatis infection is the most prevalent bacterial sexually transmitted infection with
over 130 million new cases reported annually [1]. The majority of infected women have uncomplicated
lower genital tract infections, but some women develop a persistent or ascending infection [2]. In the
latter, infection can lead to severe reproductive morbidity, including tubal factor infertility (TFI) [3].
Tissue damage resulting from chlamydial infection has been attributed to inflammatory processes in
the upper genital tract, leading to pelvic adhesions and scarring of the tubal epithelium [4].
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Laparoscopy and dye chromopertubation have remained the gold standard for assessing
tubal patency and pelvic adhesions in subfertile women [5]. Laparoscopy, however, is an
invasive and expensive procedure requiring general anesthesia. Hysterosalpingography (HSG) and
hysterosalpingosonography (HSSG) are alternative less-invasive methods for tubal evaluation, but less
accurate in identifying TFI, as peritubal adhesions cannot be detected [6].
Women with TFI have serum antibodies against C. trachomatis more often than women without
tubal pathology [7,8]. Therefore, C. trachomatis IgG antibody testing (CAT) has been introduced as
a screening test for TFI in the infertility work-up, to select high-risk patients for laparoscopic tubal
evaluation [9]. The most commonly used CAT is based on an antibody response to C. trachomatis major
outer membrane protein (MOMP). The major limitation of CAT in TFI prediction is its low specificity,
leading to a low positive predictive value (PPV) [10]. Positive CAT is only a marker of past exposure,
but does not reflect persistence or clearance of infection [7].
The persistence of C. trachomatis in the upper genital tract has been suggested as one of the key
mechanisms in the development of Fallopian tube scarring [11]. C. trachomatis TroA and HtrA are
essential proteins expressed particularly during persistent chlamydial infection [12,13]. The levels
of TroA (YtgA) have been shown to increase when C. trachomatis is cultured under iron-starvation
conditions, which is one means to induce persistence [14]. High temperature requirement protein
(HtrA) plays a role during C. trachomatis replication. HtrA levels has been shown to increase during the
developmental cycle whenC. trachomatis is cultured at the presence of penicillin, which is another means
to induce persistence in vitro [14]. Also in vivo, IgG antibody responses to C. trachomatis TroA and
HtrA are more common in patients with ascending and repeated chlamydial infections than in healthy
controls [15], and women with TFI have more often serum IgG antibodies to TroA and HtrA than
subfertile women with patent Fallopian tubes [16]. Use of such differentially expressed C. trachomatis
antigens as TroA and HtrA may offer a means to develop more specific tools for TFI diagnostics.
Our goal was to evaluate the performance of C. trachomatis TroA and HtrA antibody testing in
detecting C. trachomatis-related Fallopian tube pathology and pelvic adhesions using laparoscopy as the
reference standard, and to compare their accuracy with the most commonly used CAT (MOMP IgG).
2. Materials and Methods
2.1. Study Population
This study was performed among 116 subfertile women who had undergone laparoscopy and
tubal testing with methylene blue dye as part of their infertility evaluation: 57 Dutch women who
were part of a cohort of consecutive patients visiting the Fertility Clinic of the University Medical
Center Groningen (UMCG) between 2007–2016, and 59 Finnish women who visited the Reproductive
Medicine Unit, Helsinki University Hospital (HUH), between 2007–2010 (Figure 1). All participants
were Caucasian and had a history of at least one year of subfertility. In the Dutch cohort, laparoscopy
was performed in women who had positive CAT results, or when tubo-ovarian abnormalities were
found by ultrasound. In the Finnish cohort, laparoscopy was performed in case of severe dysmenorrhea,
suspicion of deep rectovaginal endometriosis on physical examination, or a large endometrioma or an
ovarian cyst requiring surgical treatment. Bilateral tubal occlusion found by HSSG was confirmed by
laparoscopy in the Finnish cohort.
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Figure 1. Flowchart of the number of patients (n) in the study. 88 
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perform serological assays for the present study. Serum samples of the Finnish women had been 91 
collected and analyzed for our previous studies, in which we studied the performance of C. 92 
trachomatis-specific cell-mediated and humoral immune responses in TFI prediction [17] and the 93 
prevalence of TroA and HtrA antibodies among unselected subfertile women [16]. 94 
The laparoscopic findings were retrospectively collected from the patient registries of UMCG 95 
and HUH, and scored in a standardized way by two gynecologists (T.R. and J.L.). TFI was classified 96 
according to increasing severity of tuboperitoneal adhesions and the patency of the Fallopian tubes 97 
(LS-score 0, 1, 2, 3, 4) [18]: 98 
0 = no abnormalities 99 
1 = few periadnexal adhesions and/or patent Fallopian tubes 100 
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The laparoscopic findings of endometriosis were graded according to the American Fertility 104 
Society classification [19]. Exclusion criteria for the present study were stage II-III (moderate) or IV 105 
(severe) endometriosis (n = 32), or a history of pelvic surgery other than uncomplicated 106 
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periadnexal adhesions and/or distal occlusion of at least one tube (LS score 3–4), since this has been 108 
shown to reflect chlamydia associated tubal pathology most accurately [18]. Subfertile women 109 
without TFI (LS score 0–2) served as controls. The controls had unexplained infertility, mild male 110 
factor infertility, mild endometriosis, ovulatory disorders or proximal tubal occlusions. 111 
The final study population consisted of 79 subfertile women (42 Dutch and 37 Finnish women) 112 
(Figure 1). 113 
2.2. Serological Methods 114 
IgG antibody responses to recombinant C. trachomatis TroA and HtrA were analyzed by an in-115 
house enzyme immune assay (EIA) at the Department of Virology, Helsinki University, as described 116 
earlier [15,16]. Purified TroA (CT067) and HtrA (CT823) proteins were coated (100 ng) to Nunc 117 
Figure 1. Flowchart of the number of patients (n) in the study.
Serum samples of the Dutch women were collected at the first clinic visit as a part of their
routine infertility work-up. Spare serum was cryopreserved at −20 ◦C for research purposes and
thawed to perform serological assays for the present study. Serum samples of the Finnish women
had been collected and analyzed for our previous studies, in which we studied the performance of
C. trachomatis-specific cell-mediated and humoral immune responses in TFI prediction [17] and the
prevalence of TroA and HtrA antibodies among unselected subfertile women [16].
The laparoscopic findings were retrospectively collected from the patient registries of UMCG
and HUH, and scored in a standardized way by two gynecologists (T.R. and J.L.). TFI was classified
according to increasing severity of tuboperitoneal adhesions and the patency of the Fallopian tubes
(LS-score 0, 1, 2, 3, 4) [18]:
0 = no abnormalities
1 = few periadnexal adhesions and/or patent Fallopian tubes
2 = extensive p ri dnexal adhesions and/or pr ximal occlusion of at least one tube
3 = extensive p ri dnexal adhesions and/or distal occlusion of at least one tube
4 = extensive p ri dnexal adhesions and/or distal occlusion of both tubes
The laparoscopic findings f end metriosis were graded acc rding to the American Fertility
Society classification [19]. Exclusion criteria for the present study were stage II-III (m derate) or IV
(severe) endometriosis (n = 32), or a history of pelvic surgery other than uncomplicated appendectomy
or Caesarean section (n = 5). For the present study, TFI was defined as extensive periadnexal adhesions
and/or distal occlusion of at least one tube (LS score 3–4), since this has been shown to reflect chlamydia
associated tubal pathology most accurately [18]. Subfertile women without TFI (LS score 0–2) served
as controls. The controls had unexplained infertility, mild male factor infertility, mild endometriosis,
ovulatory disorders or proximal tubal occlusions.
The final study population consisted of 79 subfertile women (42 Dutch and 37 Finnish women)
(Figure 1).
2.2. Serological Methods
IgG antibody responses to recombinant C. trachomatis TroA and HtrA were analyzed by an
in-house enzyme immune assay (EIA) at the Department of Virology, Helsinki University, as described
earlier [15,16]. Purified TroA (CT067) and HtrA (CT823) proteins were coated (100 ng) to Nunc
M xisorp ELISA plate wells. After coating, the wells were ashed and blocked with 3% BSA. Sera
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diluted 1:200 were tested, and binding was detected with 1:1000 diluted polyclonal anti-Human
IgG-HRP (Dako, Glostrup, Denmark) and 3,3’,5,5’-tetramethylbenzidine substrate (TMB, Labsystems
Diagnostics, Vantaa, Finland). Each serum sample was analyzed in duplicate in antigen-coated and
non-coated wells, and the absorbance value of the non-coated well was subtracted from the absorbance
value of the antigen-coated well. A positive serum (serum reactive with the purified protein in western
blotting) and a negative serum as well as buffer-only wells were included in each run. The cut-off
values for the assay were based on the absorbance values (mean + 2 SD) obtained from specimens
of sexually inexperienced girls, not exposed to C. trachomatis (mean age 12 years, range 8–17). TroA
antibody was detected in 8.1% (mean absorbance at 450 nm 0.216) of sera from healthy blood donors,
HtrA antibody in 5.4% (mean absorbance at 450 nm 0.113).
C. trachomatis MOMP-specific IgG antibody response had been analyzed as a part of the routine
infertility work-up in the Dutch cohort, and as part of our previous study in the Finnish cohort [17].
The serological assay for MOMP IgG detection used in both cohorts was a commercially available
ELISA kit (Medac Diagnostica, Hamburg, Germany). Sera were diluted 1:100 and tested according to
the manufacturer’s instructions. The results were expressed as a mean absorbance at 450 nm. The
cut-off value for a positive antibody result (mean optical density [OD] of the negative control +0.350)
was OD > 0.4.
2.3. Statistical Methods
Characteristics of women with and without TFI were compared using the Mann-Whitney U-test
and X2-test. For comparison of the prevalence of C. trachomatis antibodies in women with and without
TFI, X2-test was used. X2-test for trend and Kruskal-Wallis test were used to compare C. trachomatis
TroA, HtrA, and MOMP seroprevalences and to study TroA and HtrA IgG absorbance levels in relation
to the severity of TFI. The prognostic value of C. trachomatis antibody tests for TFI was analyzed by
calculating the sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive
value (NPV) for single tests and test combinations. Statistical analyses were performed by IBM SPSS
Statistics 25.0 (IBM Corp., Armonk NY, USA). p-value < 0.05 was considered statistically significant.
2.4. Ethical Approval
Dutch women attending the UMCG Fertility Clinic had approved the use of their anonymized
medical data and spare serum samples for research purposes. The procedure was approved by the
medical ethical board of the Amsterdam University Medical Centers (#10.17.0046, 16/02/2016). Use of
serological and medical data of Finnish women was approved by the Helsinki University Hospital
Ethical Committee (Dnro 29/E9/07), 19 March 2007).
3. Results
3.1. Tubal Factor Infertility (TFI) in the Study Population
In our selected study population, altogether 28 (35.4%) of the 79 women fulfilled the definition of
TFI (i.e. extensive peritubal adhesions and/or distal occlusion of at least one Fallopian tube). Tubal
occlusion was bilateral in 16 (57.1%) cases and unilateral in 12 (42.9%) cases (Figure 1). The mean age
(31.1 vs. 31.1 years, respectively) and the duration of subfertility (2.5 vs. 2.6 years, respectively) were
comparable between women with and without TFI.
3.2. Serological Results
Of the 79 women, 28 (35.4%) had C. trachomatis TroA IgG antibodies, 27 (34.2%) had HtrA IgG
antibodies, and 32 (40.5%) had IgG antibodies against C. trachomatis MOMP. Women with TFI had
more often TroA IgG (60.7% vs. 21.6%, p < 0.001) and HtrA IgG antibodies (57.1% vs. 21.6%, p = 0.001)
than women without TFI (Table 1). The difference in the presence of MOMP IgG antibodies between
TFI and non-TFI groups was not statistically significant (53.6% vs. 33.3%, p = 0.08).
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Table 2 shows the performances of single antibody tests and test combinations for TFI.C. trachomatis
TroA IgG antibody test was the best single test in detecting TFI, with an accuracy of 72.2%, sensitivity
of 60.7% and specificity of 78.4% (Table 2). PPV of TroA IgG (in our study population with 35.4%
TFI prevalence) was 60.7% and NPV 78.4%. Specificity increased to 86.3% when the combination of
TroA and HtrA IgG antibodies was used, but sensitivity decreased to 53.6%. MOMP IgG showed a
specificity of 66.9% and sensitivity of 53.6% for the detection of TFI. Combining MOMP antibodies
with TroA IgG or HtrA IgG increased specificity to 88.2%, but sensitivity of the combination was 35.7%.
Table 1. The prevalence of C. trachomatis TroA, HtrA and MOMP IgG antibodies in tubal factor infertility
(TFI) cases and controls.
TFI (N = 28) Controls (N = 51) p-Value
TroA IgG (%) 60.7 (17/28) 21.6 (11/51) 0.001
HtrA IgG (%) 57.1 (16/28) 21.6 (11/51) 0.001
MOMP IgG (%) 53.6 (15/28) 33.3 (17/51) 0.08
Microorganisms 2019, 7, 391 6 of 10
Table 2. Predictive values of single and combinations of antibody tests for detecting TFI with 95% confidence intervals (CI).
Antibody Test Sensitivity (%, 95% CI) Specificity (%, 95% CI) Accuracy (%, 95% CI) PPV (%, 95% CI) NPV (%, 95% CI)
TroA IgG 60.7 (40.6–78.5) 78.4 (64.7–88.7) 72.2 (60.9–81.7) 60.7 (45.8–73.8) 78.4 (69.2–85.5)
HtrA IgG 57.1 (37.2–75.5) 78.4 (64.7–88.7) 70.9 (59.6–80.6) 59.3 (44.1–72.9) 76.9 (68.0–84.0)
MOMP IgG 53.6 (33.9–72.5) 66.7 (52.1–79.2) 62.0 (50.4–72.7) 46.9 (34.4–59.7) 72.3 (62.7–80.3)
Test combinations
TroA + HtrA IgG 53.6 (33.9–72.5) 86.3 (73.7–94.3) 74.7 (63.6–83.8) 68.2 (49.8–82.2) 77.2 (69.1–83.6)
TroA + MOMP IgG 39.3 (21.5–59.4) 84.3 (71.4–92.3) 68.4 (56.9–78.4) 57.9 (38.5–75.1) 71.7 (64.7–77.7)
HtrA + MOMP IgG 32.1 (15.9–52.4) 90.2 (78.6–96.7) 69.6 (58.3–79.5) 64.3 (40.1–82.9) 70.8 (64.9–76.0)
TroA + HtrA + MOMP IgG 35.7 (18.6–55.9) 88.2 (76.1–95.6) 69.6 (58.3–79.5) 62.5 (40.4–80.4) 71.4 (65.1–77.0)
PPV, positive predictive value; NPV, negative predictive value.
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3.3. Serum Antibody Levels by the Severity of TFI
The prevalence of C. trachomatis TroA IgG (p < 0.001) and HtrA IgG (p = 0.001) antibodies increased
by increasing severity of TFI (Figure 2). Also, the mean absorbance level (A450nm) of TroA IgG, and
HtrA IgG antibodies increased by increasing severity of TFI, being highest in the LS-score group 4
(mean A450nm [SD, range]) 1.54 [1.54, 0.07—3.83]) for TroA and 1.41 [0.007—3.81]) for HtrA).
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Figure 2. The prevalence (%) of C. tracho atis r I , tr I , and MOMP IgG antibody by the
severity of TFI. The severity of pelvic adhesions as graded by the laparoscopy score (LS-score) scale
modified from Land et al., 1998 [18]: 0 = no abnormalities, 1 = few periadnexal adhesions and/or
patent Fallopian tubes, 2 = extensive periadnexal adhesions and/or proximal occlusion of at least one
tube, 3 = extensive periadnexal adhesions and/or distal occlusion of at least one tube, 4 = extensive
periadnexal adhesions and/or distal occlusion of both tubes.
4. Discussion
The aim of this study was to evaluate the perfor ance of C. trachomatis TroA IgG and HtrA IgG
in diagnosing TFI, and to compare the to the ost co only used CAT (MOMP IgG). We found
that TroA and HtrA antibodies were strongly associated with TFI, but the antibody response against
C. trachomatis MOMP did not show this association. This is in agreement with several earlier studies
that have observed a relatively low diagnostic accuracy of MOMP IgG in TFI prediction [8,9,17,20].
MOMP is a protein accounting for the majority of the outer membrane of the bacterium [14]. Antibody
response against MOMP reflects previous exposure to the pathogen, but does not provide information
about clearance or persistence of C. trachomatis [7]. Our study confirms the hypothesis that particularly
prolonged exposure to C. trachomatis leads to chronic inflammatory responses and reproductive
sequelae, as TroA and HtrA are specific C. trachomatis proteins produced during persistent stages of
chlamydial infection.
We were the first to evaluate the performance of C. trachomatis TroA and HtrA antibody tests
in subfertile women, by using laparoscopic results as the gold standard for TFI. Ideally, a test with
high NPV and high sensitivity could r le out C. trachomatis-related TFI and avoid unnec ssary and
inva ive examina ions in p tients. In our s udy, we could not identify this ideal test, as the best single
test for TFI detectio was TroA IgG antibody with only mo erate sensiti ity (60.7%) and NPV (78.4%).
Combin g TroA IgG with HtrA r MOMP IgG did not improv the sen itiv ty of the test combina ion.
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The combination of HtrA and MOMP IgG had the highest specificity, but the sensitivity was low
because of many false negative test results.
The seropositivity rates and the serum absorbance levels of TroA and HtrA antibodies increased
with increasing severity of TFI. This finding is in line with previous studies showing a linear relationship
between serum MOMP IgG titers and severity of tubal damage [21,22]. In these studies, high antibody
titers were also observed in some women with normal pelvic anatomy, whereas in our study, no
patients with normal pelvic anatomy had high TroA IgG and HtrA IgG absorbance values (mean
A450nm ≥ 1.0).
The predictive value of CAT for TFI is highly dependent on the definition of TFI and the selection
of cases and controls. Our cohort comprised of 79 subfertile women with laparoscopically evaluated
tubal status from the fertility centers of two large university hospitals in Europe, and TFI was uniformly
defined. However, the retrospective nature of our study has potential sources of bias, including
incomplete documentation and the variability in the quality of data reported by laparoscopists. The
majority of Dutch women included in the study were selected for laparoscopy based on their initial
CAT result, and therefore, more CAT positive women had laparoscopies than CAT negative women. In
the Finnish cohort, women were selected for laparoscopy based on their risk for severe endometriosis
or abnormalities on HSSG. This selection bias explains the high TFI rate in our study, influencing the
predictive values, which are known to be dependent on the prevalence of the disease. We acknowledge
the limited number of patients in the final cohort of our study. However, this is an exploratory study
focusing on chlamydia-related TFI, and the study population consisted of women with the highest risk
of previous chlamydial infection. Although the absolute predictive values may be overestimated, the
relative differences between the performances of the tests will be accurate and thus applicable into the
study populations with lower TFI prevalence.
Despite the overwhelming evidence that C. trachomatis infection is causally linked to salpingitis
and TFI, we found the predictive value of TroA and HtrA C. trachomatis serology in diagnosing tubal
damage and pelvic adhesions to be only moderate. Not every patient with TFI has been infected with C.
trachomatis or will develop a humoral immune response to C. trachomatis. Tubal damage can be caused
also by other pelvic infections, such as Neisseria gonorrhoeae or Mycoplasma genitalium infection [23].
Furthermore, as tubal tissue damage is immune-mediated, the development of TFI is affected by the
host immune response [24,25] and the virulence of the causative organism [11,26]. It is also worth
noticing that in our study not all subfertile women with positive serum TroA and HtrA IgG antibody
tests had tubal damage or pelvic adhesions. This may be explained by the fact that tubal pathology not
necessarily appears as visible occlusions. Silent, persistent chlamydial infections may cause non-visible
mucosal damage, impairing the function of the tube and the likelihood of natural conception [27].
Thus, it would be interesting to study the time to pregnancy in TroA and HtrA IgG positive patients
without visible tubal pathology at laparoscopy.
We confirmed that the accuracy of CAT by MOMP IgG in the prediction of TFI is low, whereas C.
trachomatis TroA IgG and HtrA IgG are more accurate tests for TFI due to their higher specificity and
higher PPV. However, their sensitivity and NPV are still too low to justify their use as a screening test in
clinical practice. Chlamydial pelvic infections and TFI are both complex, multifactorial diseases and it
seems highly unlikely that one single test would be specific enough to predict TFI as a late consequence
of chlamydial infection. Because antibody responses to TroA and HtrA may indicate the course of
chlamydial infection more accurately than MOMP IgG, and tissue damage is known to be affected by
immunogenetic variation in the host [25], it might be interesting to study TroA and HtrA serology in
combination with genetic profiling, to identify women with the highest risk for late complications.
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